Journal Article

COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial

Wilschut, Jeroen M., van der Waarden, Nancy, Alexopoulos, Dimitrios, Van Mieghem, Nicolas M., van Vliet, Ria, Nuis, Rutger-Jan, Diletti, Roberto, Vlachojannis, Georgios J., Krucoff, Mitchell W., Angiolillo, Dominick J., Vogel, Rosanne F., Delewi, Ronak, Zijlstra, Felix, Smits, Pieter C., Montalescot, Gilles, Paradies, Valeria, Lemmert, Miguel E.

2020

Overview

Dual antiplatelet therapy constitutes the cornerstone of medical treatment in patients with ST elevation myocardial infarction (STEMI). However, oral antiplatelet agents, such as prasugrel or ticagrelor, are characterized by slow gastrointestinal drug absorption in the acute phase of STEMI, leading to decreased bioavailability and therefore delayed onset of platelet inhibition. Evidence suggests that administration of crushed tablets of the P2Y12 inhibitor prasugrel improves drug absorption and achieves earlier antiplatelet effects in STEMI patients undergoing primary percutaneous coronary intervention (PCI). However, the clinical implications of these pharmacokinetic and pharmacodynamic findings are unknown. The present study is designed to test the hypothesis that patients presenting with STEMI planned for primary PCI will have improved markers of optimal reperfusion and clinical outcomes by prehospital administration of crushed tablets of prasugrel loading dose. COMPARE CRUSH (NCT03296540) is a randomized trial in a regionally organized ambulance care setting evaluating the efficacy and safety of pre-hospital loading dose with prasugrel crushed tablets versus integral tablets in approximately 674 patients presenting with STEMI planned for primary PCI. The independent primary endpoints are percentage of patients reaching thrombolysis in myocardial infarction (TIMI) flow grade 3 in the infarct-related artery at initial angiography, or achieving ≥70% ST-segment elevation resolution at 1 hour post-PCI. Secondary clinical endpoints are death, myocardial infarction, revascularization, and stent thrombosis followed up to 1 year. Moreover, the primary safety endpoint is bleeding events assessed at 48 hours. The COMPARE CRUSH trial will assess whether prehospital administration of loading dose prasugrel in form of crushed tablets - which is expected to provide faster platelet inhibition compared to standard treatment with integral tablets - results in improved reperfusion and clinical outcomes. RCT# NCT03296540

• Publisher: Elsevier Inc,Elsevier Limited,Elsevier
• Subject: Absorption / Administration, Oral / Aged / Angiography / Angioplasty / Antiplatelet therapy / Bioavailability / Bleeding / Blood platelets / Coronary Angiography / Crushing / Dose-Response Relationship, Drug / Drug dosages / Drug therapy / Female / Health services / Heart attacks / Humans / Hypotheses / Implants / Integrals / Laboratories / Life Sciences / Male / Medical imaging / Medical treatment / Middle Aged / Multicenter Studies as Topic / Myocardial infarction / Patients / Percutaneous Coronary Intervention / Pharmacodynamics / Pharmacokinetics / Pharmacology / Platelet Aggregation Inhibitors - administration & dosage / Platelets / Prasugrel Hydrochloride - administration & dosage / Preoperative Period / Randomized Controlled Trials as Topic / Reperfusion / Safety / ST Elevation Myocardial Infarction - diagnosis / ST Elevation Myocardial Infarction - therapy / Tablets / Thromboembolism / Thrombolysis / Thrombolytic drugs / Thrombosis / Treatment Outcome / Veins & arteries